BIO - Bio-Rad Laboratories, Inc.
NYSE
->
Healthcare
->
Medical Devices
Hercules,
United States
Type: Equity
BIO price evolution
BIO
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $406.91 | $433.28 | $403.81 | |
| Short term investments | $1214.75 | $1217.95 | $1208.89 | |
| Net receivables | $461.94 | $445.51 | $444.81 | $489.02 |
| Inventory | $804.28 | $803.69 | $783.37 | $780.52 |
| Total current assets | $3055.62 | $3056.25 | $3060.94 | $3048.33 |
| Long term investments | $5099.55 | $8018.38 | $7698.07 | |
| Property, plant & equipment | $719.17 | $715.24 | $711.28 | $723.74 |
| Goodwill & intangible assets | $719.21 | $726.42 | $734.08 | |
| Total noncurrent assets | $6632.19 | $9548.96 | $9250.74 | |
| Total investments | $6314.31 | $9236.34 | $8906.96 | |
| Total assets | $10603.47 | $9688.45 | $12609.89 | $12299.07 |
| Current liabilities | ||||
| Accounts payable | $390.39 | $126.69 | $102.75 | $144.63 |
| Deferred revenue | ||||
| Short long term debt | $42 | $40.52 | $40.87 | |
| Total current liabilities | $497.94 | $486.96 | $466.15 | $522.8 |
| Long term debt | $1200.06 | $1199.72 | $1359.19 | $1364.53 |
| Total noncurrent liabilities | $2422.7 | $3092.61 | $3035.14 | |
| Total debt | $1392.69 | $1399.72 | $1405.39 | |
| Total liabilities | $3115.61 | $2909.66 | $3558.76 | $3557.94 |
| Shareholders' equity | ||||
| Retained earnings | $8132.23 | $7479.06 | $9644.55 | $9260.63 |
| Other shareholder equity | -$329.57 | -$452.36 | -$425.97 | -$336.04 |
| Total shareholder equity | $6778.79 | $9051.13 | $8741.13 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $403.81 | $434.21 | $470.78 | $662.21 |
| Short term investments | $1208.89 | $1362.02 | $404.69 | $334.47 |
| Net receivables | $489.02 | $494.64 | $423.54 | $419.42 |
| Inventory | $780.52 | $719.32 | $572.24 | $622.25 |
| Total current assets | $3048.33 | $3157.98 | $1989.09 | $2139.84 |
| Long term investments | $7698.07 | $8830.89 | $14387.01 | $9561.14 |
| Property, plant & equipment | $723.74 | $679.56 | $695.75 | $693.51 |
| Goodwill & intangible assets | $734.08 | $738.63 | $601.28 | $491.41 |
| Total noncurrent assets | $9250.74 | $10343.69 | $15786.71 | $10832.78 |
| Total investments | $8906.96 | $10192.91 | $14791.7 | $9895.61 |
| Total assets | $12299.07 | $13501.67 | $17775.79 | $12972.62 |
| Current liabilities | ||||
| Accounts payable | $144.63 | $329.83 | $141.94 | $139.45 |
| Deferred revenue | $52.21 | $50.85 | $42.47 | |
| Short long term debt | $40.87 | $36.8 | $36.92 | $38.3 |
| Total current liabilities | $522.8 | $568.71 | $680.94 | $631.54 |
| Long term debt | $1364.53 | $1197.72 | $186.45 | $187.39 |
| Total noncurrent liabilities | $3035.14 | $3317.71 | $3427.72 | $2461.14 |
| Total debt | $1405.39 | $1388.11 | $223.38 | $225.69 |
| Total liabilities | $3557.94 | $3886.41 | $4108.66 | $3092.68 |
| Shareholders' equity | ||||
| Retained earnings | $9260.63 | $9898.2 | $13507.24 | $9268.01 |
| Other shareholder equity | -$336.04 | $9615.25 | -$175.55 | $282.46 |
| Total shareholder equity | $8741.13 | $9615.25 | $13667.13 | $9879.94 |
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $649.73 | $610.82 | $681.18 | |
| Cost of revenue | $284.85 | $314.82 | ||
| Gross Profit | $355.9 | $325.97 | $366.36 | |
| Operating activities | ||||
| Research & development | $66.38 | $63.9 | ||
| Selling, general & administrative | $214.88 | $207.15 | ||
| Total operating expenses | $261.94 | $281.26 | $271.05 | |
| Operating income | $44.71 | $95.32 | ||
| Income from continuing operations | ||||
| EBIT | $503.36 | $440.75 | ||
| Income tax expense | $208.45 | $107.16 | $78.68 | |
| Interest expense | $796.57 | $12.28 | $12.36 | |
| Net income | ||||
| Net income | $653.17 | $383.92 | $349.71 | |
| Income (for common shares) | $383.92 | $349.71 | ||
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $2671.26 | $2802.25 | $2922.55 | $2545.63 |
| Cost of revenue | $1244.32 | $1234.92 | $1281.88 | $1107.8 |
| Gross Profit | $1426.95 | $1567.33 | $1640.66 | $1437.82 |
| Operating activities | ||||
| Research & development | $247.43 | $256.89 | $271.66 | $226.6 |
| Selling, general & administrative | $841.72 | $827.83 | $879.57 | $800.27 |
| Total operating expenses | $1089.15 | $1084.71 | $1151.23 | $1026.87 |
| Operating income | $337.8 | $482.62 | $489.43 | $410.96 |
| Income from continuing operations | ||||
| EBIT | -$800.66 | -$4666.16 | $5439.7 | $4929.5 |
| Income tax expense | -$212.78 | -$1076.74 | $1192.25 | $1101.37 |
| Interest expense | $49.44 | $38.11 | $1.55 | $21.86 |
| Net income | ||||
| Net income | -$637.32 | -$3627.53 | $4245.9 | $3806.27 |
| Income (for common shares) | -$637.32 | -$3627.53 | $4245.9 | $3806.27 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$2165.49 | $383.92 | $349.71 | |
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | $2.5 | |||
| Stock-based compensation | ||||
| Total cash flows from operations | $97.65 | $69.79 | $81.05 | |
| Investing activities | ||||
| Capital expenditures | -$42.22 | -$40.15 | -$42.14 | |
| Investments | $11.29 | -$2.94 | $111.83 | |
| Total cash flows from investing | -$129.66 | -$30.93 | -$43.09 | $72.2 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | -$96.32 | $0.76 | -$195.68 | |
| Net borrowings | -$0.12 | -$0.73 | -$0.12 | |
| Total cash flows from financing | -$192.55 | -$96.59 | $0.02 | -$200.62 |
| Effect of exchange rate | -$1.02 | $3.83 | $2.66 | -$6.57 |
| Change in cash and equivalents | $7.82 | -$26.04 | $29.38 | -$53.95 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$637.32 | -$3627.53 | $4245.9 | $3806.27 |
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | $2.5 | -$99.39 | -$125.52 | -$84.42 |
| Stock-based compensation | ||||
| Total cash flows from operations | $374.94 | $194.45 | $656.52 | $575.33 |
| Investing activities | ||||
| Capital expenditures | -$156.47 | -$112.62 | -$120.75 | -$98.85 |
| Investments | $174.18 | -$994.21 | -$538.17 | $119.6 |
| Total cash flows from investing | $20.21 | -$1207.59 | -$784.44 | -$60.25 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | -$410.24 | -$198.12 | -$29.37 | -$79.81 |
| Net borrowings | -$0.47 | $1185.71 | -$3.02 | -$426.94 |
| Total cash flows from financing | -$425.65 | $973.58 | -$55.43 | -$523.04 |
| Effect of exchange rate | $0.32 | $2.98 | -$12.64 | $12.43 |
| Change in cash and equivalents | -$30.18 | -$36.59 | -$195.98 | $4.46 |
News
Fundamentals
| Market cap | $9.57B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 28.00M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | 2.79% |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 0.41 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 6.14 |
| Quick ratio | 4.52 |